Using AI to Discover Dual-purpose Therapeutics Targeting Aging and Disease at the same time

Add to your list(s) Download to your calendar using vCal

• Alex Zhavoronkov, PhD - Insilico Medicine
• Saturday 26 November 2022, 13:00-14:00
• Virtual Talk (Zoom).

If you have a question about this talk, please contact Brandon Spencer Lockey.

Insilico Medicine is a leader in next generation artificial intelligence technologies for drug discovery and biomarker development. They have raised over $415 million in multiple rounds, nominated 8 preclinical candidates and entered human clinical trials with an AI-discovered and AI-designed antifibrotic, and recently struck a deal with Sanofi worth up to $1.2 billion. Alex is an adjunct professor of artificial intelligence at the Buck Institute for Research on Aging and has published over 160 peer-reviewed academic publications and two books since 2014, and has pledged his commitment to the Longevity Field.

https://us02web.zoom.us/meeting/register/tZAqcuioqTMqGtZhgBH5SVpxOy8nbL910ILV

This talk is part of the Cambridge University Longevity Society 2023-2024 Series series.

This talk is included in these lists:

• Biology
• Cambridge Neuroscience Seminars
• Cambridge University Longevity Society 2023-2024 Series
• Cambridge talks
• Chris Davis' list
• Featured lists
• Life Science
• Life Sciences
• Neuroscience
• Neuroscience Seminars
• Neuroscience Seminars
• Stem Cells & Regenerative Medicine
• Virtual Talk (Zoom)
• dh539

Note that ex-directory lists are not shown.